Dallas, TX: ReportsandReports announce it will carry Astellas Pharma Inc.: PharmaVitae Profile Market Research Report in its Store.

Browse complete Astellas Pharma Inc.: PharmaVitae Profile Report

This analysis examines the historical and forecast performance for Astellas in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

• Benchmark Astellas’s performance against key rivals in the prescription pharmaceutical sector
• Determine the long-term outlook of Astellas’s diverse prescription pharmaceutical portfolio
• Evaluate the unique corporate strategies being pursued by Astellas in its domestic Japanese market and in the US

Table of Content

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001-13 5

Financial performance, 2001-13 7

Astellas: PharmaVitae forecasts at a glance 8

Strategic insight 9

M&A helps reinforce focus on Rx pharmaceuticals 9

Cost containment and share buybacks drive investor returns post-merger 11

Flagship organ rejection franchise likely to exhibit strong defense against generic compeition 13

Lifecycle management and generic insulation vital in sustaining medium-term organ rejection revenues 13

Long-term focus on organ rejection underscored by continuing pipeline efforts 15

SWOT analysis 17

Strengths 17

Weaknesses 20

Opportunities 21

Threats 22

CHAPTER 3 QUARTERLY NEWS UPDATE 26

Product developments 26

Deals and alliances 28

Product deals 28

Technology deals 28

Company announcements 29

Future product milestones 29

CHAPTER 4 COMPANY INTRODUCTION 30

Key findings 30

Background 31

Key corporate developments 31

M&A history 34

Merger of Yamanouchi and Fujisawa 34

Acquisiiton of Agensys 35

Current corporate structure 36

Prescription (Rx) pharmaceuticals 36

Other 36

CHAPTER 5 COMPANY SALES 37

Key findings 37

Prescription pharmaceutical sales and growth rate analysis, 2001-13 38

Historical analysis 39

Forecast analysis 40

Product analysis 41

Product analysis, 2001-07 42

Growth drivers 43

Growth resistors 44

Product analysis, 2007-13 45

Growth drivers 46

Growth resistors 48

Therapy area analysis 49

Therapy area analysis, 2001-07 50

Therapy area analysis, 2007-13 51

Therapy area focus, 2001-13 52

Geographic analysis 53

Geographic analysis, 2001-07 54

Geographic analysis, 2007-13 56

Geographic focus, 2001-13 58

Launch/core/expiry analysis 59

Explanation of launch/core/expiry analysis 59

Launch analysis, 2007-13 60

Core analysis, 2007-13 61

Expiry analysis, 2007-13 62

Launch/core/expiry configuration, 2007-13 63

Molecule type analysis 64

Molecule type analysis, 2001-07 65

Molecule type analysis, 2007-13 65

Externalization analysis 66

Externalization analysis, 2001-07 67

Externalization analysis, 2007-13 69

CHAPTER 6 COMPANY FINANCIALS 71

Key findings 71

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 73

Financial statements, 2001-07 74

Profit and loss account, 2001-07 74

Balance sheet, 2001-07 75

Operating costs and profit analysis 77

Operating costs and profit analysis, 2001-07 78

Operating cost ratio and profit margin analysis, 2001-07 79

Operating cost ratio and profit margin analysis, 2007-13 80

Operating costs and profit analysis, 2007-13 82

Return on capital employed analysis 83

Capital employed analysis, 2001-07 84

Return on capital employed (RoCE) analysis, 2001-07 86

Market capitalization analysis 89

Market capitalization analysis, 2001-07 89

Total shareholder returns analysis, 2001-07 90

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 92

Key findings 92

Overview 93

Cardiovascular 94

Micardis 94

Overview 95

Sales forecast 97

Lipitor 100

Overview 101

Sales forecast 102

Kynapid 104

Overview 105

Sales forecast 106

Immunology and inflammation 109

Prograf/Advagraf 109

Overview 110

Sales forecast 112

Urology and gender-specific health 116

Vesicare 116

Overview 117

Sales forecast 118

Harnal 121

Overview 122

Sales forecast 123

Infectious diseases 125

Arbelic 125

Overview 126

Sales forecast 127

CHAPTER 8 APPENDIX 131

R&D pipeline 131

References 132

Abbreviations 133

Exchange rates 134

Browse complete Astellas Pharma Inc.: PharmaVitae Profile Report

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports RSS

Browse all Latest Report

Related Reports:

Astellas Pharma Inc.-Company Report

Astellas Pharma Inc. – SWOT Analysis

Astellas Pharma Inc.

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/